Literature DB >> 29450699

Consolidation/Tumor Ratio on Chest Computed Tomography as Predictor of Postoperative Nodal Upstaging in Clinical T1N0 Lung Cancer.

Youngkyu Moon1, Jae Kil Park2, Kyo Young Lee3, Min Namkoong2, Seha Ahn2.   

Abstract

BACKGROUND: In clinical T1N0 peripheral lung cancers, lymph node upstaging is occasionally encountered postoperatively. However, nodal upstaging is rare in lung cancers presenting as ground-glass opacities. The aim of this study was to determine if lymph node upstaging could be reliably extrapolated from parameters such the consolidation/tumor ratio of chest computed tomography.
METHODS: We conducted a retrospective study of 486 patients treated for peripheral clinical T1N0 non-small cell lung cancer, each undergoing lobectomy with mediastinal lymph node dissection. We compared preoperative variables in the pathologic N0 and nodal upstaging groups, analyzing such variables to determine factors predictive of lymph node upstaging.
RESULTS: Of the 486 patients studied, lymph node upstaging occurred in 42 (8.6%). In the upstaging group, the mean nodule diameter exceeded that of the pathologic N0 group (2.3 vs 1.9 cm, respectively; p < 0.001), and the mean consolidation/tumor ratio was larger in the upstaging group than the pN0 group (0.95 vs 0.68, respectively; p < 0.001). Nodule diameter and consolidation/tumor ratio emerged as significant predictive factors for lymph node upstaging after surgery in a multivariate analysis (hazard ratio [HR] 2.259, p = 0.039; HR 173.645, p = 0.001, respectively).
CONCLUSIONS: Consolidation/tumor ratio and nodule diameter are significant predictive factors of postoperative lymph node upstaging. The higher the consolidation/tumor ratio and smaller the nodule diameter, the less likely the occurrence of postoperative lymph upstaging would be in clinical T1N0 peripheral non-small cell lung cancer.

Entities:  

Mesh:

Year:  2018        PMID: 29450699     DOI: 10.1007/s00268-018-4543-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  20 in total

1.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

Review 2.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Authors:  William D Travis; Hisao Asamura; Alexander A Bankier; Mary Beth Beasley; Frank Detterbeck; Douglas B Flieder; Jin Mo Goo; Heber MacMahon; David Naidich; Andrew G Nicholson; Charles A Powell; Mathias Prokop; Ramón Rami-Porta; Valerie Rusch; Paul van Schil; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2016-04-21       Impact factor: 15.609

3.  The effectiveness of mediastinal lymph node evaluation in a patient with ground glass opacity tumor.

Authors:  Youngkyu Moon; Sook Whan Sung; Min Namkoong; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

4.  The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.

Authors:  Takashi Eguchi; Kyuichi Kadota; Bernard J Park; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

5.  Stage migration: results of lymph node dissection in the era of modern imaging and invasive staging for lung cancer.

Authors:  Bilal H Kirmani; Robert C Rintoul; Thida Win; Cormac Magee; Lavinia Magee; Cliff Choong; Francis C Wells; Aman S Coonar
Journal:  Eur J Cardiothorac Surg       Date:  2012-04-23       Impact factor: 4.191

6.  Re-Assessment of Intentional Extended Segmentectomy for Clinical T1aN0 Non-Small Cell Lung Cancer.

Authors:  Wataru Nishio; Masahiro Yoshimura; Yoshimasa Maniwa; Yoshitaka Kitamura; Kenta Tane; Daisuke Takenaka; Shuji Adachi
Journal:  Ann Thorac Surg       Date:  2016-08-12       Impact factor: 4.330

7.  Clinicopathologic Factors Associated With Occult Lymph Node Metastasis in Patients With Clinically Diagnosed N0 Lung Adenocarcinoma.

Authors:  Youngkyu Moon; Kyung Soo Kim; Kyo Young Lee; Sook Whan Sung; Young Kyoon Kim; Jae Kil Park
Journal:  Ann Thorac Surg       Date:  2016-03-05       Impact factor: 4.330

8.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.

Authors:  Paul De Leyn; Christophe Dooms; Jaroslaw Kuzdzal; Didier Lardinois; Bernward Passlick; Ramon Rami-Porta; Akif Turna; Paul Van Schil; Frederico Venuta; David Waller; Walter Weder; Marcin Zielinski
Journal:  Eur J Cardiothorac Surg       Date:  2014-02-26       Impact factor: 4.191

9.  Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma.

Authors:  Tomoharu Yoshiya; Takahiro Mimae; Yasuhiro Tsutani; Norifumi Tsubokawa; Shinsuke Sasada; Yoshihiro Miyata; Kei Kushitani; Yukio Takeshima; Shuji Murakami; Hiroyuki Ito; Haruhiko Nakayama; Morihito Okada
Journal:  Ann Thorac Surg       Date:  2016-06-23       Impact factor: 4.330

Review 10.  Lung Cancer Statistics.

Authors:  Lindsey A Torre; Rebecca L Siegel; Ahmedin Jemal
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

View more
  10 in total

1.  Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.

Authors:  Youngkyu Moon; Si Young Choi; Jae Kil Park; Kyo Young Lee
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

2.  Prognosis of upstaged N1 and N2 disease after curative resection in patients with clinical N0 non-small cell lung cancer.

Authors:  Jae Kil Park; Youngkyu Moon
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

3.  The prognosis of stage I non-small cell lung cancer with visceral pleural invasion and whole pleural adhesion after video-assisted thoracoscopic lobectomy: A single center retrospective study.

Authors:  Youngkyu Moon; Si Young Choi; Mi Hyoung Moon
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

4.  Validation of completion lobectomy after wedge resection for ≤20 mm non-small cell lung cancer.

Authors:  Ryuichi Yoshimura; Hiroyuki Deguchi; Makoto Tomoyasu; Satoshi Kudo; Wataru Shigeeda; Yuka Kaneko; Hironaga Kanno; Hajime Saito
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

5.  Prognostic factors in stage IB non-small cell lung cancer according to the 8th edition of the TNM staging system after curative resection.

Authors:  Youngkyu Moon; Si Young Choi; Jae Kil Park; Kyo Young Lee
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

6.  Predictive factors for invasive adenocarcinoma in patients with clinical non-invasive or minimally invasive lung cancer.

Authors:  Youngkyu Moon; Jae Kil Park; Kyo Young Lee; Seha Ahn; Jinwon Shin
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

7.  Prognosis after wedge resection in patients with 8th edition TNM stage IA1 and IA2 non-small cell lung cancer.

Authors:  Youngkyu Moon; Jae Kil Park; Kyo Young Lee; Eun Sung Kim
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

8.  Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule.

Authors:  Jong Hui Suh; Jae Kil Park; Youngkyu Moon
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

9.  Initial experience with uniportal video-assisted thoracoscopic surgery for the treatment of lung cancer performed by a surgeon who did not have previous experience performing multiportal thoracoscopic surgery: a single center retrospective study.

Authors:  Youngkyu Moon
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

10.  The value of pulmonary nodule diameter and consolidation/tumor rate in the prediction of lymph node metastasis in early-stage (cT1N0M0) lung adenocarcinoma.

Authors:  Weipeng Shao; Zhaohua Zhang; Zhan Liu; Zhenrong Zhang; Hongliang Sun; Xiaowei Wang; Hongxiang Feng; Chaoyang Liang; Deruo Liu
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.